ArticleThe Annals of pharmacotherapy2023

Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations.

Yifang Eva Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.